Aurinia Pharmaceuticals Inc. Prepares for Jefferies Healthcare Conference to Showcase Innovations

Aurinia Pharmaceuticals Prepares for Jefferies Healthcare Conference

Aurinia Pharmaceuticals Inc., a biopharmaceutical company with a specialized focus on therapies for autoimmune diseases, gears up for its participation in the Jefferies Healthcare Conference in London, scheduled for November 19-21, 2024. The conference serves as a crucial venue for the company to engage directly with investors through one-on-one meetings, highlighting its commitment to transparency and stakeholder engagement. Among its activities, Aurinia's management team is set to conduct a fireside chat and Q&A session on November 20 at 12:00 PM GMT/7:00 AM EST, although this session will not be available for live streaming. This event is not only an opportunity for Aurinia to showcase its innovations but also to strengthen its relationships within the healthcare investment community.

Central to Aurinia's mission is its flagship product, LUPKYNIS® (voclosporin), which made history as the first FDA-approved oral treatment specifically designed for adults suffering from active lupus nephritis. Launched in January 2021, LUPKYNIS® addresses a significant unmet medical need in the autoimmune disease landscape, reaffirming Aurinia's role as a pioneer in this area. The company demonstrates its dedication to improving patient outcomes through innovative treatments, establishing itself as a leader in developing targeted therapies for complex autoimmune diseases.

In addition to LUPKYNIS®, Aurinia is advancing its drug development pipeline with AUR200, a promising candidate that aims to be a best-in-class therapy. AUR200 targets both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), two critical components involved in the pathophysiology of autoimmune diseases. By focusing on these targets, Aurinia aims to offer more effective treatment options for patients grappling with various autoimmune conditions. The strategic direction of the company underscores its commitment to addressing the pressing health challenges faced by individuals with autoimmune diseases, further solidifying its position within the biopharmaceutical sector.

The Jefferies Healthcare Conference presents Aurinia with a vital platform to underscore its advancements in autoimmune disease therapies and foster meaningful investor relationships. As the company navigates this pivotal event, its focus remains on innovation and patient-centric solutions, reinforcing its role as a key player in the biopharmaceutical industry dedicated to addressing significant health challenges.